More on J&J Q4: Net profit $3.52B

J&J (JNJ +0.85%) Q4 net profit $3.52B vs $2.57B a year earlier.

Domestic sales +7.4%, international sales +2.4%

2013 results were "led by the outstanding performance in our pharmaceutical business, the strength of key brands in our U.S. OTC and other consumer businesses, and continued progress in integrating Synthes into our Medical Devices and Diagnostics business," says J&J CEO Alex Gorsky.

J&J expects 2014 EPS of $5.75-5.85 vs consensus of $5.85. (PR)


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs